Form 8-K - Current report:
SEC Accession No. 0001193125-24-098524
Filing Date
2024-04-17
Accepted
2024-04-17 06:35:32
Documents
14
Period of Report
2024-04-17
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d787749d8k.htm   iXBRL 8-K 24474
2 EX-99.1 d787749dex991.htm EX-99.1 20047
  Complete submission text file 0001193125-24-098524.txt   168794

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA sage-20240417.xsd EX-101.SCH 2848
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE sage-20240417_lab.xml EX-101.LAB 17236
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE sage-20240417_pre.xml EX-101.PRE 10811
18 EXTRACTED XBRL INSTANCE DOCUMENT d787749d8k_htm.xml XML 3551
Mailing Address 215 FIRST STREET CAMBRIDGE MA 02142
Business Address 215 FIRST STREET CAMBRIDGE MA 02142 617-299-8380
Sage Therapeutics, Inc. (Filer) CIK: 0001597553 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36544 | Film No.: 24849343
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)